Avaleht/Aktsiad/XFOR

XFOR

USD

X4 Pharmaceuticals Inc. Common Stock

$3.970-0.030 (-0.750%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$4.000

Kõrge

$4.120

Madal

$3.940

Maht

0.20M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

314.5M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

4.09M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $1.35Praegune $3.970Kõrge $26.82

Seotud uudised

10. nov 2025 · 12:09

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals with a Buy and raises the price target from $3.5 to $5.

Vaata rohkem

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5

27. okt 2025 · 23:05

GlobeNewswire

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its

Vaata rohkem

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

24. okt 2025 · 04:37

GlobeNewswire

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its

Vaata rohkem